Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neoadjuvant SBRT in Localized Advanced HNSCC
Sponsor: Jiang Feng
Summary
The response rate of HNSCC to immune checkpoint blockade was not satisfied. Improving the mPR rate of neoadjuvant immunotherapy through the combination with other treatment methods is an important way to further improve the prognosis of such patients. This study aims to explore the efficacy and safety of PD-1 monoclonal antibody with neoadjvant SBRT and chemotherapy. The triple mode not only can Increase the effectiveness of neoadjuvant therapy,meanwhile,the in situ tumor vaccine inoculation effect generated by enhancing the release of specific antigens after tumor radiotherapy with PD-1 monoclonal antibody achieves a sustained anti-tumor immune effect throughout the body, reducing postoperative adjuvant radiotherapy and chemotherapy. The triple mode has important exploratory value in achieving high quality and long-term survival for patients, and may provides a more efficient mode for locally advanced HNSCC.
Official title: Neoadjuvant Stereotactic Body Radiotherapy(SBRT)Combined With Immunotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
81
Start Date
2023-10-01
Completion Date
2026-12-31
Last Updated
2024-03-12
Healthy Volunteers
No
Conditions
Interventions
SBRT+immunochemotherpy
SBRT radiotherapy,followed with PD-1 monoclonal antibody and TP chemotherapy
Immunochemotherapy
PD-1 monoclonal antibody and TP chemotheapy
cetuximab+immunochemotharpy
PD-1 monoclonal antibody and TP chemotheapy combined with cetuximab
Locations (1)
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China